{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:42:57Z","timestamp":1792730577640,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for the development of CIDP and patients\u2019 treatment response, this research effort seeks to identify potential clinical factors that may influence disease progression and overall treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter, retrospective analysis, we have screened 197 CIDP patients who presented to the University Hospitals in D\u00fcsseldorf, Berlin, Cologne, Essen, Magdeburg and Munich between 2018 and 2022. We utilized the respective hospital information system and examined baseline data with clinical examination, medical letters, laboratory results, antibody status, nerve conduction studies, imaging and biopsy findings. Aside from clinical baseline data, we analyzed treatment outcomes using the Standard of Care (SOC) definition, as well as a comparison of an early (within the first 12\u00a0months after manifestation) versus late (more than 12\u00a0months after manifestation) onset of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In terms of treatment, most patients received intravenous immunoglobulin (56%) or prednisolone (39%) as their first therapy. Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score. SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Timely diagnosis, prompt initiation of treatment and careful monitoring of treatment response are essential for the prevention of long-term disability in CIDP and suggest a \u201chit hard and early\u201d treatment paradigm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-024-12548-1","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:25:30Z","timestamp":1720686330000},"page":"5930-5943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1463-1961","authenticated-orcid":false,"given":"Paula","family":"Quint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kohle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menekse","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Tamburrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Mausberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Szepanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Maisam","family":"Afzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katinka","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"R\u00e4uber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Voth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Masanneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Willison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vogelsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Stascheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"3\u20134","key":"12548_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000494291","volume":"52","author":"MC Broers","year":"2019","unstructured":"Broers MC et al (2019) Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Neuroepidemiology 52(3\u20134):161\u2013172","journal-title":"Neuroepidemiology"},{"issue":"6 Pt 2","key":"12548_CR2","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/j.lpm.2013.01.056","volume":"42","author":"PY Van den Bergh","year":"2013","unstructured":"Van den Bergh PY, Rajabally YA (2013) Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 42(6 Pt 2):e203\u2013e215","journal-title":"Presse Med"},{"issue":"9","key":"12548_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"EK Mathey","year":"2015","unstructured":"Mathey EK et al (2015) Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86(9):973\u2013985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"12548_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"H K\u00f6ller","year":"2005","unstructured":"K\u00f6ller H et al (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352(13):1343\u20131356","journal-title":"N Engl J Med"},{"issue":"1","key":"12548_CR5","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1038\/s41598-017-14853-4","volume":"7","author":"L Querol","year":"2017","unstructured":"Querol L et al (2017) Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 7(1):14411","journal-title":"Sci Rep"},{"issue":"1","key":"12548_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1529-8027.2012.00372.x","volume":"17","author":"JJ Devaux","year":"2012","unstructured":"Devaux JJ, Odaka M, Yuki N (2012) Nodal proteins are target antigens in Guillain-Barre syndrome. J Peripher Nerv Syst 17(1):62\u201371","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"12548_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014533","volume":"6","author":"C Cifuentes-Diaz","year":"2011","unstructured":"Cifuentes-Diaz C et al (2011) Nodes of ranvier and paranodes in chronic acquired neuropathies. PLoS ONE 6(1):e14533","journal-title":"PLoS ONE"},{"issue":"7","key":"12548_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/brain\/awx124","volume":"140","author":"E Delmont","year":"2017","unstructured":"Delmont E et al (2017) Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain 140(7):1851\u20131858","journal-title":"Brain"},{"issue":"6","key":"12548_CR9","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1007\/s10072-021-05811-0","volume":"43","author":"G Liberatore","year":"2022","unstructured":"Liberatore G et al (2022) Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. Neurol Sci 43(6):3939\u20133947","journal-title":"Neurol Sci"},{"issue":"8","key":"12548_CR10","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00415-020-09823-2","volume":"268","author":"L Tang","year":"2021","unstructured":"Tang L et al (2021) Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. J Neurol 268(8):2757\u20132768","journal-title":"J Neurol"},{"issue":"11","key":"12548_CR11","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK et al (2021) European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. Eur J Neurol 28(11):3556\u20133583","journal-title":"Eur J Neurol"},{"issue":"10","key":"12548_CR12","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L et al (2021) Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol 268(10):3706\u20133716","journal-title":"J Neurol"},{"key":"12548_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-981-32-9636-7_21","volume":"1190","author":"S Kuwabara","year":"2019","unstructured":"Kuwabara S, Misawa S (2019) Chronic inflammatory demyelinating polyneuropathy. Adv Exp Med Biol 1190:333\u2013343","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"12548_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","volume":"90","author":"PE Doneddu","year":"2019","unstructured":"Doneddu PE et al (2019) Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 90(2):125\u2013132","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12548_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.653734","volume":"12","author":"D Menon","year":"2021","unstructured":"Menon D, Katzberg HD, Bril V (2021) Treatment approaches for Atypical CIDP. Front Neurol 12:653734","journal-title":"Front Neurol"},{"issue":"8","key":"12548_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","volume":"18","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C et al (2019) Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 18(8):784\u2013794","journal-title":"Lancet Neurol"},{"key":"12548_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/jnnp-2023-332398","volume":"95","author":"L Wieske","year":"2023","unstructured":"Wieske L et al (2023) Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 95:595\u2013604","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"12548_CR18","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3390\/cells12202456","volume":"12","author":"M Oeztuerk","year":"2023","unstructured":"Oeztuerk M et al (2023) Current biomarker strategies in autoimmune neuromuscular diseases. Cells 12(20):2456","journal-title":"Cells"},{"key":"12548_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.723009","volume":"12","author":"F Stascheit","year":"2021","unstructured":"Stascheit F et al (2021) Calprotectin in chronic inflammatory demyelinating polyneuropathy and variants-a potential novel biomarker of disease activity. Front Neurol 12:723009","journal-title":"Front Neurol"},{"key":"12548_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000884","author":"AK Mausberg","year":"2020","unstructured":"Mausberg AK et al (2020) NK cell markers predict the efficacy of IV immunoglobulins in CIDP. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000884","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"12548_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acn3.275","volume":"3","author":"M Stettner","year":"2016","unstructured":"Stettner M et al (2016) Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Ann Clin Transl Neurol 3(2):88\u2013100","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"12548_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ene.14044","volume":"27","author":"PE Doneddu","year":"2020","unstructured":"Doneddu PE et al (2020) Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. Eur J Neurol 27(1):136\u2013143","journal-title":"Eur J Neurol"},{"issue":"9","key":"12548_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S (2019) Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 90(9):981\u2013987","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"12548_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27046","volume":"63","author":"AM Stino","year":"2021","unstructured":"Stino AM et al (2021) Chronic inflammatory demyelinating polyradiculoneuropathy\u2014diagnostic pitfalls and treatment approach. Muscle Nerve 63(2):157\u2013169","journal-title":"Muscle Nerve"},{"issue":"1","key":"12548_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mus.27325","volume":"64","author":"JA Allen","year":"2021","unstructured":"Allen JA (2021) Measuring treatment response to chronic inflammatory demyelinating polyneuropathy in clinical practice: more than just asking. Muscle Nerve 64(1):1\u20133","journal-title":"Muscle Nerve"},{"issue":"2","key":"12548_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/nmt-2016-0058","volume":"7","author":"HD Katzberg","year":"2017","unstructured":"Katzberg HD, Latov N, Walker FO (2017) Measuring disease activity and clinical response during maintenance therapy in CIDP: from ICE trial outcome measures to future clinical biomarkers. Neurodegener Dis Manag 7(2):147\u2013156","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"12548_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R et al (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50(2):195\u2013201","journal-title":"Ann Neurol"},{"issue":"11","key":"12548_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Meche FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 14(11):1103\u20131109","journal-title":"Muscle Nerve"},{"issue":"1","key":"12548_CR29","first-page":"CD010369","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL et al (2017) Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 1(1):CD010369","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"12548_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","volume":"17","author":"D Cocito","year":"2010","unstructured":"Cocito D et al (2010) A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 17(2):289\u2013294","journal-title":"Eur J Neurol"},{"issue":"2","key":"12548_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11940-010-0058-9","volume":"12","author":"EE Robertson","year":"2010","unstructured":"Robertson EE, Donofrio PD (2010) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 12(2):84\u201394","journal-title":"Curr Treat Options Neurol"},{"key":"12548_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038411","author":"PA McCombe","year":"2022","unstructured":"McCombe PA et al (2022) Sex differences in Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1038411","journal-title":"Front Immunol"},{"issue":"6","key":"12548_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/mus.24978","volume":"53","author":"A Abraham","year":"2016","unstructured":"Abraham A et al (2016) Frequent laboratory abnormalities in CIDP patients. Muscle Nerve 53(6):862\u2013865","journal-title":"Muscle Nerve"},{"issue":"11","key":"12548_CR34","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1093\/brain\/awaa265","volume":"143","author":"F Eftimov","year":"2020","unstructured":"Eftimov F et al (2020) Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 143(11):3214\u20133224","journal-title":"Brain"},{"issue":"5","key":"12548_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/mus.27708","volume":"66","author":"JA Allen","year":"2022","unstructured":"Allen JA, Lewis RA (2022) Diagnosis of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 66(5):545\u2013551","journal-title":"Muscle Nerve"},{"issue":"8","key":"12548_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2712","volume":"12","author":"KL Gable","year":"2022","unstructured":"Gable KL et al (2022) A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy. Brain Behav 12(8):e2712","journal-title":"Brain Behav"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12548-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12548-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:19:37Z","timestamp":1725524377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12548-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12548"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12548-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MSc has received speaker honoraria from Alexion Pharmaceuticals, argenx, Bayer, Biogen, CSL Behring, Genzyme, Grifols, Merck, Miltenyi Biotec, Novartis, Roche, Teva, and Hormosan Pharma. He is vice chairman of the medical advisory board of the German Myasthenia Gravis Society. HPH received fees for serving on SC from Octapharma and Sanofi. MS served on the scientifc advisory boards and\/or received speaker honoraria, travel funding or honoraria for medical writing from Argenex; Bayer; Biogen Idec; Biotest; CSL Behring; Genzyme; Grifols; Immunovant; Kedrion; Merck; Novartis; Octapharma; PPTA; Roche; Sanofi-Aventis; TEVA; UCB. FS received speaking honoria and honoria for attendance of advisory boards from argnx. The other authors have no conflicts of interest to declare. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}